Aller au contenu principal
xMedica

NCT07784725ClinicalTrials.gov

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Phase 32 500 participants recherchés220 sites16 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 6 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-19
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 212 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,500 participants (target), run at 220 sites, across 16 countries.

How this score is built
  • Enrolment34/40

    2,500 participants (target)

  • Site count25/25

    212 sites

  • Country count15/15

    16 countries

  • Planned duration8/10

    Planned over about 34 months

  • Sponsor scale10/10

    AstraZeneca has led 1,017 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

This is a Phase III, global, randomised, parallel-group, double-blind, multicentre study to assess the efficacy and safety of AZD6234 compared with placebo, administered SC once weekly in adults with obesity or overweight with at least one weight-related comorbidity without T2DM. Eligible participants will be randomized to either receive AZD6234 or matching placebo respectively.

Affections

  • Obesity or Overweight

Éligibilité

Éligibilité
SexeTous
Âges18 Years – Aucun maximum
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 × ULN * AST ≥ 3.0 × ULN * TBL \> 1.5 × ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 3
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuQUADRUPLE (4)
Recrutement2 500 participants recherchés

Promoteur et collaborateurs

  • AstraZeneca Promoteur

Groupes et interventions

  • AZD6234 Dose 1EXPERIMENTAL

    AZD6234 Dose 1

  • AZD6234 Dose 2EXPERIMENTAL

    AZD6234 Dose 2

  • PlaceboPLACEBO_COMPARATOR

    Matching placebo

Interventions

  • Médicament Lenbelintide

    IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

  • Médicament Placebo

    Placebo matching IMP dose injected subcutaneously, once a week.

Critères de jugement

  1. Critère de jugement principal

    Percent change in body weight from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in percent body weight change

    Délai 68 weeks

  2. Critère de jugement secondaire

    Absolute change in weight (kg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on absolute change in weight

    Délai 68 weeks

  3. Critère de jugement secondaire

    Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 5%

    Délai 68 weeks

  4. Critère de jugement secondaire

    Achievement of at least 10% body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 10%

    Délai 68 weeks

  5. Critère de jugement secondaire

    Change in waist circumference (cm) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on waist circumference change

    Délai 68 weeks

  6. Critère de jugement secondaire

    Percent change in triglycerides from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on triglycerides percent change

    Délai 68 weeks

  7. Critère de jugement secondaire

    Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on systolic blood pressure change

    Délai 68 weeks

  8. Critère de jugement secondaire

    Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset

    Body Composition Sub-study: To evaluate the effect of AZD6234 as compared to placebo on body composition change in the DXA subset of participants

    Délai 68 weeks

Dates

Dates
Date de début19 août 2026 (réelle)
Achèvement principal11 août 2028 (estimée)
Achèvement21 mai 2029 (estimée)
Première publication25 août 2026 (réelle)
Dernière mise à jour30 octobre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisoctobre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

76 sites sont en recrutement

Argentina

Argentina
ÉtablissementVilleÉtat ou régionStatut
Research SiteBuenos AiresEn recrutement
Research SiteBuenos AiresEn recrutement
Research SiteCiudad de Buenos AiresEn recrutement
Research SiteMendozaEn recrutement
Research SiteRamos MejíaPas encore en recrutement
Research SiteRosarioEn recrutement
Research SiteSan NicolásPas encore en recrutement

Australia

Australia
ÉtablissementVilleÉtat ou régionStatut
Research SiteBotanyEn recrutement
Research SiteCamberwellEn recrutement
Research SiteCharlestownEn recrutement
Research SiteSt AlbansEn recrutement
Research SiteSt LeonardsEn recrutement
Research SiteWaitaraEn recrutement

Brazil

Brazil
ÉtablissementVilleÉtat ou régionStatut
Research SiteBelo HorizontePas encore en recrutement
Research SiteBrasíliaPas encore en recrutement
Research SiteCampinasPas encore en recrutement
Research SiteCampinasPas encore en recrutement
Research SiteCuritibaRetiré
Research SiteCuritibaPas encore en recrutement
Research SiteCuritibaPas encore en recrutement
Research SiteNatalPas encore en recrutement
Research SitePorto AlegrePas encore en recrutement
Research SiteRio de JaneiroPas encore en recrutement
Research SiteSão José dos CamposPas encore en recrutement
Research SiteSão PauloPas encore en recrutement

Bulgaria

Bulgaria
ÉtablissementVilleÉtat ou régionStatut
Research SiteMontanaPas encore en recrutement
Research SitePlevenPas encore en recrutement
Research SitePlovdivEn recrutement
Research SiteSofiaEn recrutement
Research SiteSofiaEn recrutement
Research SiteSofiaEn recrutement
Research SiteVarnaPas encore en recrutement
Research SiteYambolEn recrutement

Canada

Canada
ÉtablissementVilleÉtat ou régionStatut
Research SiteBramptonOntarioEn recrutement
Research SiteCalgaryAlbertaEn recrutement
Research SiteGuelphOntarioEn recrutement
Research SiteHamiltonOntarioEn recrutement
Research SiteMississaugaOntarioEn recrutement
Research SiteMonctonNew BrunswickEn recrutement
Research SiteMontrealQuebecEn recrutement
Research SiteNew WestminsterBritish ColumbiaEn recrutement
Research SiteNorth YorkOntarioEn recrutement
Research SiteQuébecQuebecEn recrutement
Research SiteQuébecQuebecEn recrutement
Research SiteSaint-Charles-BorroméeQuebecEn recrutement
Research SiteScarborough VillageOntarioEn recrutement
Research SiteSherbrookeQuebecEn recrutement
Research SiteStoney CreekOntarioEn recrutement
Research SiteStouffvilleOntarioEn recrutement
Research SiteSurreyBritish ColumbiaRetiré

170 sites supplémentaires sont indiqués dans la fiche du registre.

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 30 octobre 2026

    Site ajouté

    8 sites added (220 total)

    212220